STEVEN KALFUS: Open Payments
NPI 1801938865 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,587 in 138 payments from 22 companies in 2025. Trend: 2023 $7,770 · 2024 $9,558 · 2025 $3,587
Food & beverage: $2,687Speaker / faculty: $900
| Company | Payments | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 15 | $1,239 |
| ABBVIE INC. | 27 | $574 |
| Gilead Sciences, Inc. | 15 | $345 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 20 | $232 |
| Madrigal Pharmaceuticals | 12 | $198 |
| QOL Medical, LLC | 8 | $167 |
| Ardelyx, Inc. | 8 | $148 |
| Aimmune Therapeutics, Inc. | 6 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $113 |
| GENZYME CORPORATION | 4 | $82 |
Products named: IQIRVO, MAVYRET, REZDIFFRA, Sucraid, CREON, IBSRELA, XIFAXAN, DUPIXENT.
Industry payments across AZ — which companies pay providers there.
